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Abstract
Background
To find prognostic biomarkers in pretreatment dynamic contrast-enhanced MRI (DCE-MRI)
water-exchange-modified (WX) kinetic parameters for advanced hepatocellular carcinoma
(HCC) treated with antiangiogenic monotherapy.
Methods
Twenty patients with advanced HCC underwent DCE-MRI and were subsequently treated
with sunitinib. Pretreatment DCE-MRI data on advanced HCC were analyzed using five
different WX kinetic models: the Tofts-Kety (WX-TK), extended TK (WX-ETK), two compart-
ment exchange, adiabatic approximation to tissue homogeneity (WX-AATH), and distrib-
uted parameter (WX-DP) models. The total hepatic blood flow, arterial flow fraction (γ),
arterial blood flow (BFA), portal blood flow, blood volume, mean transit time, permeability-
surface area product, fractional interstitial volume (vI), extraction fraction, mean intracellular
water molecule lifetime (τC), and fractional intracellular volume (vC) were calculated. After
receiver operating characteristic analysis with leave-one-out cross-validation, individual
parameters for each model were assessed in terms of 1-year-survival (1YS) discrimination
using Kaplan-Meier analysis, and association with overall survival (OS) using univariate
Cox regression analysis with permutation testing.
Results
TheWX-TK-model-derived γ (P = 0.022) and vI (P = 0.010), andWX-ETK-model-derived τC
(P = 0.023) and vC (P = 0.042) were statistically significant prognostic biomarkers for 1YS.
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Increase in the WX-DP-model-derived BFA (P = 0.025) and decrease in the WX-TK, WX-
ETK, WX-AATH, and WX-DP-model-derived vC (P = 0.034, P = 0.038, P = 0.028, P = 0.041,
respectively) were significantly associated with an increase in OS.
Conclusions
TheWX-ETK-model-derived vC was an effective prognostic biomarker for advanced HCC
treated with sunitinib.
Introduction
Dynamic contrast-enhanced MRI (DCE-MRI) has a potential role in the monitoring of antian-
giogenic therapy for hepatocellular carcinoma (HCC) [1–3]. Pharmacokinetic analysis of
DCE-MRI data is widely applied in oncology for the measurement of vascular and tissue physi-
ology. Extracted kinetic parameters are used for the characterization and classification of dis-
ease processes and for monitoring of treatment effects. The reliability of these measurements
depends on the use of a model that accurately describes the relationship of the contrast agent
(CA) concentration to the underlying tissue physiology. Because the liver receives a dual blood
supply from the hepatic artery and the portal vein, dual-input tracer kinetic models hold prom-
ise for quantitative analysis of hepatic perfusion [4–7].
However, it is still unclear to what extent modeling assumptions, particularly regarding
water exchange between tissue compartments, impact on parameter estimates derived from
DCE-MRI data. The commonly used standard approach to DCE-MRI data analysis does not
take water exchange into account, thus effectively assuming that water exchange is at the fast
exchange limit (FXL) [8]. However, this assumption is physically unreasonable because devia-
tions from the FXL condition occur when the compartmental distributions of CA and water
molecules are different [9–11]. Water-exchange-modified (WX) tracer kinetic analysis of
DCE-MRI data allows evaluation of intercompartmental water interchange kinetics, thus
enabling additional estimation of the rate of cellular water turnover, which may play a role as a
surrogate marker for quantifying the most crucial ongoing cellular metabolic turnover [12].
Therefore, it is warranted to use a model that includes water exchange effects in order to dem-
onstrate whether water exchange has an impact on the prediction of the clinical outcome.
To date, no effort has been made to seek data comparing the relative performance of differ-
ent tracer kinetic models that measure intercompartmental water exchange kinetics in
DCE-MRI data regarding HCC. Our aim in this study was to find effective prognostic kinetic
biomarkers of advanced HCC treated with sunitinib monotherapy for 1-year survival (1YS)
and overall survival (OS), in comparison with five different WX dual-input tracer kinetic mod-
els for pretreatment liver DCE-MRI.
Materials and Methods
Subjects
The protocol for this phase II clinical trial on advanced HCC [1] was in compliance with
Health Insurance Portability and Accountability Act regulations and was approved by the insti-
tutional review board at Dana-Farber/Harvard Cancer Center (Boston, MA). All patients were
required to provide written informed consent before study participation, according to institu-
tional and federal guidelines. All patient record/information and image data were anonymized
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and de-identified prior to retrospective analysis in this study. The eligibility criteria have been
detailed previously [1]. The patient exclusion criteria included concurrent malignancies; signif-
icant medical comorbidities; significant cardiovascular disease, including uncontrolled hyper-
tension, myocardial infarction, and unstable angina; New York Heart Association grade 2 or
greater congestive heart failure; prolongation of QTc of more than 450 msec in screening ECG
or history of familial long QT syndrome; a history of bleeding; proteinuria at baseline (more
than 2 g/d); pregnancy or lactation; CNS metastases; or an inability to provide written
informed consent. A total of 34 patients with histologically confirmed advanced HCC were
enrolled. Fourteen of these patients were subsequently excluded because DCE-MRI data were
not retrievable for this perfusion study; thus, 20 patients were included in the current study.
This study cohort included 18 men and 2 women (age range, 30–79 years; mean age, 59.55
years). Full details of the clinical data of these patients have been reported in [1].
DCE-MRI
Pretreatment DCE-MRI of the liver was performed with a 1.5 Tesla MRI system with a phased
array body coil (Avanto; Siemens, New York, NY). First, a coronal T1-weighted three-dimen-
sional (3D) volumetric interpolated breath-hold examination (VIBE) sequence of varying flip
angles of 10, 15, 30, 60, and 90 degrees was performed before CA injection. Thereafter, a total
of 0.1 mmol/kg bodyweight of the CA, gadolinium-diethylenetriaminepentaacetic acid (Gd-
DTPA) (Magnevist; Berlex, Montville, NJ) was injected at 2 mL/sec, followed by a saline chase
of 20 mL at a rate of 2 mL/sec through a 20-gauge peripheral intravenous line in the arm. A
series of coronal T1-weighted 3D VIBE images was obtained after a 5-second delay following
the initiation of CA injection, and the scanning was continued for up to 4 minutes and 30 sec-
onds. The acquisition parameters were as follows: TR = 5 msec, TE = 1.58 msec, 5-mm slice
thickness, 0-mm interslice gap, 20 slices, 352×384 matrix, 15-degree flip angle, and field of
view of 366×400 mm. Two consecutive 7-second acquisitions were repeated 10 times with a
delay of 21 seconds between them. The scanning time of every acquisition was 14 seconds with
breath holding, followed by a break of 21 seconds.
Data Processing
An image post-processing algorithm was coded in C/C++ with Visual Studio 2010 Professional
Edition (Microsoft, Redmond, WA, USA). Anonymized DCE-MRI data were imported into
our in-house software program and were analyzed offline by use of five different WX tracer
kinetic models: the Tofts-Kety (WX-TK) model [13] based on a two-site-exchange (2SX)
model for transcytolemmal exchange [14], and the extended TK (WX-ETK) model [15], two
compartment exchange (WX-2CX) model [16,17], adiabatic approximation to the tissue
homogeneity (WX-AATH) model [18,19], and distributed parameter (WX-DP) model [20,21]
based on a three-site-two-exchange (3S2X) model for transendothelial and transcytolemmal
water exchange [9] (see S1 Appendix). These models provided the following parameters: total
hepatic blood flow (BF, mL/min/100 g), arterial flow fraction (γ), arterial blood flow (BFA, mL/
min/100 g), portal blood flow (BFPV, mL/min/100 g), blood volume (BV, mL/100 g), mean
transit time (MTT, min), capillary wall permeability-surface area product (PS, mL/min/100 g),
fractional interstitial volume (vI), extraction fraction (E), mean intracellular water molecule
lifetime (τC, sec), and fractional intracellular volume (vC). A list of the various parameters and
their definitions is provided in Table 1.
For each patient, the region of interest (ROI) of a primary HCC lesion was outlined by an
oncologic surgeon [K.H., with 10 years of experience in abdominal CT/MRI interpretation] in
the central portions of the imaging volume for reducing inflow effects and wrap-around
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Table 1. Symbols and definitions for kinetic parameters.
Term Deﬁnition Unit of Measure
CA Arterial blood concentration of tracer g/mL
CPV Portal blood concentration of tracer g/mL
CP Mean concentration of tracer in the plasma compartment g/mL
C I Mean concentration of tracer in the interstitial compartment g/mL
CT Concentration of tracer in tissue g/mL
EA Relative signal enhancement in artery None
EPV Relative signal enhancement in portal vein None
ET Relative signal enhancement in tissue None
RT Tissue residue function None
QP Impulse response function of the plasma compartment mL/min/mL
QI Impulse response function of the interstitial compartment mL/min/mL
QT Impulse response function of the tissue mL/min/mL
F Total hepatic plasma ﬂow mL/min
γ Arterial ﬂow fraction None
FA Arterial plasma ﬂow mL/min
FPV Portal plasma ﬂow mL/min
BF Total hepatic blood ﬂow mL/min/100 g
BFA Arterial blood ﬂow mL/min/100 g
BFPV Portal blood ﬂow mL/min/100 g
BV Blood volume mL/100 g
MTT Mean transit time min
PS Capillary wall permeability-surface area product mL/min (or mL/min/100
g)
PSC Cell membrane permeability-surface area product mL/min (or mL/min/100
g)
vB Fractional blood volume None
vP Fractional plasma volume None
vI Fractional interstitial volume None
vC Fractional intracellular volume None
E Extraction fraction None
HLV Hematocrit in major (large) vessels None
HSV Hematocrit in small vessels None
M Tissue mass g
ρT Tissue density g/cm
3
VP Volume of the plasma compartment mL
VI Volume of the interstitial compartment mL
VC Volume of the intracellular compartment mL
VT Tissue volume mL
F/VT Total hepatic perfusion mL/min/mL
FA/VT Arterial perfusion mL/min/mL
FPV/VT Portal perfusion mL/min/mL
KTrans = EF/
VT
Volume transfer constant between the plasma and interstitial
compartments
mL/min/mL
VP/F Capillary transit time min
VP/PS Capillary leakage time min
tLag,T Difference in bolus arrival time between CA (or CPV) and CT min
τB Mean intravascular water molecule lifetime sec
(Continued)
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artifacts. Additional ROIs (mean size: 5.2 mm2) were placed within the aorta and the major
portal vein branch for each patient, and a dual-input approach was used for analysis of the
DCE-MR images [22]. The arterial input function (AIF) and the portal-venous input function
(PVIF) were fitted by use of a sums-of-exponentials model [23] that describes the first-pass
and recirculating inputs (see S1 Appendix). The tissue enhancement curve ET(t) for each voxel
within the tumor ROIs was fitted separately with the five WX models. For mitigating a poten-
tial error in parameter estimation due to the discrete approximation of the continuous formula
of the tissue concentration-time curve CT(t) [24,25], an analytic solution for CT(t) for each
model was derived by incorporation of the AIF and PVIF models (see S1 Appendix). Model fit-
ting was performed by use of a constrained nonlinear optimization algorithm based on MIN-
PACK-1 [26] that yields the sum of squared residues as a measure of the goodness of fit, and
allows upper and lower bounding constraints to be placed on each parameter [27].
To account for the difference in bolus arrival time between the various parts of the liver and
the combined input (i.e., AIF and PVIF), an additional parameter tLag,T (min) was included in
the expression for CT(t) so that an adjustable delay was imposed relative to the dual input. The
mean parameter value in the tumor ROI was taken as the representative parameter value for
the tumor.
Antiangiogenic Treatment
The treatment schedule and dose modification schema have been detailed previously [1].
Briefly, patients received sunitinib at a dose of 37.5 mg daily by mouth for 4 weeks, followed by
2 weeks of rest, in 6-week cycles. Patients with grade 3 or 4 toxicities underwent dose reduction
to 25 or 12.5 mg daily, respectively. Treatment was continued until progression, unacceptable
toxicity, or withdrawal of consent. Patients were followed until death; one patient was alive at
the end of the study, and thus the patient was censored. For this patient cohort, the median sur-
vival time was 11.42 months.
Statistical Analysis
OS was defined as the time from the start of treatment to the date of death or of the last follow-
up. Because the median survival time of patients was 11.42 months (i.e., approximately one
year), and this value divides the study population into two balanced survival groups, the sur-
vival risk was estimated as one year. For each model and each kinetic parameter, the optimal
parameter cut-off (threshold) value for predicting 1YS was estimated by means of receiver
operating characteristic (ROC) analysis [28,29]. Because the sample size was small, a leave-
one-out cross-validation (LOOCV) method, which is known to provide an unbiased estimate
even in case of small samples [28,29] was used in the ROC analysis as follows: At each iteration
of the LOOCV method, one of the patients was left out, and the parameter values of the
Table 1. (Continued)
Term Deﬁnition Unit of Measure
τI Mean intrainterstitial water molecule lifetime sec
τC Mean intracellular water molecule lifetime sec
KBI Blood-to-interstitium water transfer rate sec
-1
KIB Interstitium-to-blood water transfer rate sec
-1
KCI Cell-to-interstitium water transfer rate sec
-1
KIC Interstitium-to-cell water transfer rate sec
-1
doi:10.1371/journal.pone.0136725.t001
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remaining patients were subjected to the ROC analysis over the two survival groups of patients
for generating an ROC curve. The point closest to the top-left corner on the ROC curve, i.e.,
the point that provides min{(1−sensitivities)2 + (1−specificities)2}, was identified as a parame-
ter cut-off value. At the end of each iteration, the left-out patient was categorized into either
the “low-risk” or “high-risk” group based on the parameter cut-off value. This process of ROC
curve and cut-off value estimation was repeated at each LOOCV iteration, until all of the
patients had been left out once and categorized to either the low-risk or high-risk group.
Finally, after the LOOCV iterations had been completed, the cut-off value that had the highest
frequency during the LOOCV iterations was identified as an optimal cut-off value for the
parameter, and Kaplan-Meier analysis with log-rank test was performed for comparing the two
groups generated during the LOOCV iterations.
Kaplan-Meier survival curves for patients in the low- and high-risk groups were constructed
for display of the proportion of patients alive at any given time. The statistical significance in
the difference between these Kaplan-Meier curves was evaluated by use of the log-rank statistic
and its permutation-based significance test [29], in which 1000 random permutations were
performed and the associated P values were calculated.
For association of a kinetic parameter with OS, univariate Cox proportional hazard regres-
sion analysis concerning the continuous parameter values was performed for testing of individ-
ual kinetic parameters for each WX kinetic model. For each parameter, P values were
computed based on 1000 random permutations. The hazard ratio (HR) was defined as the
ratio of hazards for a two-fold change in the parameter values. The HR was equal to exp(b),
where b is the Cox regression coefficient. Statistical analyses were performed by use of statisti-
cal software R (version 3.0.1) and BRB-ArrayTools (version 4.4.0) [30–32].
Results
Examples of fitting of the five different WX dual-input tracer kinetic models to a voxel-level
enhancement curve within HCC, the fitted ET(t), and the corresponding impulse response
function QT(t) are shown in Fig 1. Fig 2 shows two examples of cases from each of the high-
and low-risk groups, with voxel-level fittings and parameter maps generated by use of the five
WX models. Table 2 summarizes the mean values for the different parameters for the different
WX models.
One-year Survival
Table 3 shows the optimized cut-off values of the parameters determined by ROC analysis with
LOOCV for each model along with the P values for the log-rank permutation test. For the WX-
2CX, WX-AATH andWX-DP model, the cross-validated Kaplan-Meier curves were not sig-
nificantly different between the two groups (P>0.05). Only the WX-TK-model-derived γ and
vI, and the WX-ETK-model-derived τC and vC were significant biomarkers for 1YS (Fig 3). The
WX-TK-model-derived γ and vI were both lower in the high-risk than in the low-risk group,
with cut-off values of 0.733 (P = 0.022) and 0.300 (P = 0.010), respectively. The WX-ETK-
model-derived τC and vC were both higher in the high-risk than in the low-risk group, with
cut-off values of 0.927 sec (P = 0.023) and 0.611 (P = 0.042), respectively.
Overall Survival
Table 4 shows the hazard ratios and corresponding P values for the parameters determined by
the univariate Cox proportional hazard model for each kinetic model. The results showed that
the WX-TK (HR = 21.51, P = 0.034), WX-ETK (HR = 8.418, P = 0.038), WX-AATH
(HR = 10.14, P = 0.028), and WX-DP-model-derived vC (HR = 4.213, P = 0.041), and the
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Fig 1. Example of fitting of arterial and portal-venous curves and tissue enhancement curves with various models.Graphs illustrate examples of (A
and B) fitting of the arterial and portal input enhancement curves, (C and D) fitting of the five different models to a voxel enhancement curve which was
sampled from the HCC, and (E and F) their corresponding impulse response curves (i.e.,QT(t) = (F/VT)  RT(t)) where two different cases are shown in the left
and right columns. WX = water-exchange-modified, TK = Tofts-Kety, ETK = extended Tofts-Kety. 2CX = two compartment exchange, AATH = adiabatic
approximation to tissue homogeneity, and DP = distributed parameter.
doi:10.1371/journal.pone.0136725.g001
Fig 2. Example of kinetic parameter maps derived from variousmodels. Parametric maps of total hepatic blood flow (BF), arterial flow fraction (γ),
arterial blood flow (BFA), portal blood flow (BFPV), blood volume (BV), mean transit time (MTT), capillary wall permeability-surface area product (PS),
fractional interstitial volume (vI), extraction fraction (E), mean intracellular water molecule lifetime (τC), and fractional intracellular volume (vC) for HCC in (A) a
low-risk man aged 52 years who survived for 23.87 months, and (B) a high-risk man aged 72 years who survived for 8.53 months. WX = water-exchange-
modified, TK = Tofts-Kety, ETK = extended Tofts-Kety, 2CX = two compartment exchange, AATH = adiabatic approximation to tissue homogeneity, and
DP = distributed parameter.
doi:10.1371/journal.pone.0136725.g002
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WX-DP-model-derived BFA (HR = 0.716, P = 0.025), were associated with OS, indicating that
the risk of death rises by approximately 35.9%, 23.7%, 26.1%, and 15.5% for an increase of 0.1
Table 2. Parameter values derived from the five different WX kinetic models.
Parameter Mean ± SD for high- and low-risk populations
WX-TK WX-ETK WX-2CX WX-AATH WX-DP
BF 133.4 ± 86.17 36.74 ± 21.78 49.94 ± 26.89 49.20 ± 24.17 53.47 ± 28.13
γ 0.702 ± 0.255 0.459 ± 0.220 0.730 ± 0.256 0.637 ± 0.284 0.517 ± 0.263
BFA 95.36 ± 81.05 17.56 ± 17.90 38.71 ± 27.23 33.50 ± 22.58 29.44 ± 22.88
BFPV 38.09 ± 39.04 19.18 ± 13.51 11.23 ± 14.95 15.70 ± 15.34 24.03 ± 18.35
BV 46.10 ± 27.61 18.45 ± 9.339 17.89 ± 8.733 18.97 ± 8.092 21.01 ± 10.35
MTT 1.315 ± 2.066 4.605 ± 2.739 2.212 ± 1.916 1.817 ± 1.583 2.398 ± 2.768
PS 98.42 ± 66.30 31.63 ± 22.40 16.22 ± 10.58 20.03 ± 12.42 5.452 ± 3.649
vI 0.257 ± 0.091 0.171 ± 0.076 0.181 ± 0.108 0.163 ± 0.073 0.220 ± 0.088
E 0.606 ± 0.057 0.651 ± 0.104 0.346 ± 0.136 0.407 ± 0.119 0.197 ± 0.183
τC 0.871 ± 0.684 1.050 ± 0.521 0.657 ± 0.645 1.212 ± 0.977 0.657 ± 0.627
vC 0.743 ± 0.091 0.637 ± 0.111 0.633 ± 0.139 0.639 ± 0.114 0.561 ± 0.146
RMSE 0.179 ± 0.126 0.152 ± 0.092 0.160 ± 0.108 0.151 ± 0.101 0.168 ± 0.128
Note.—SD = standard deviation, WX = water-exchange-modiﬁed, TK = Tofts-Kety, ETK = extended Tofts-Kety, 2CX = two compartment exchange,
AATH = adiabatic approximation to the tissue homogeneity, DP = distributed parameter, BF = total hepatic blood ﬂow (in mL/min/100 g), γ = arterial ﬂow
fraction (unitless), BFA = arterial blood ﬂow (in mL/min/100 g), BFPV = portal blood ﬂow (in mL/min/100 g), BV = blood volume (in mL/100 g), MTT = mean
transit time (in min), PS = capillary wall permeability-surface area product (in mL/min/100 g), vI = fractional interstitial volume (unitless), E = extraction
fraction (unitless), τC = mean intracellular water molecule lifetime (sec), vC = fractional intracellular volume (unitless), and RMSE = root-mean-square error
between original and ﬁtted ET(t).
doi:10.1371/journal.pone.0136725.t002
Table 3. Optimal cut-off values of parameters and their log-rank test results from leave-one-out cross-validated Kaplan-Meier analysis in terms of
1-year survival.
Parameter Cut-off value (P-value)
WX-TK WX-ETK WX-2CX WX-AATH WX-DP
BF 111.5 (0.345) 36.66 (0.315) 56.04 (0.220) 56.23 (0.315) 59.22 (0.682)
γ 0.833 (0.022)* 0.475 (0.871) 0.763 (0.277) 0.591 (0.338) 0.572 (0.080)
BFA 47.19 (0.172) 12.09 (0.359) 39.18 (0.662) 36.42 (0.952) 28.58 (0.662)
BFPV 10.45 (0.776) 23.99 (0.447) 5.592 (0.233) 10.36 (0.795) 15.03 (0.491)
BV 37.27 (0.345) 16.89 (0.315) 20.66 (0.379) 21.30 (0.168) 18.69 (0.634)
MTT 0.380 (0.442) 5.575 (0.597) 1.709 (0.341) 1.333 (0.163) 1.414 (0.163)
PS 80.52 (0.504) 26.31 (0.315) 19.95 (0.725) 20.04 (0.644) 2.697 (0.782)
vI 0.300 (0.010)* 0.123 (0.161) 0.207 (0.344) 0.142 (0.206) 0.209 (0.460)
E 0.603 (0.682) 0.635 (0.981) 0.298 (0.367) 0.413 (0.224) 0.118 (0.377)
τC 0.482 (0.199) 0.927 (0.023)* 0.376 (0.831) 0.819 (0.588) 0.284 (0.702)
vC 0.728 (0.131) 0.611 (0.042)* 0.533 (0.282) 0.646 (0.468) 0.518 (0.194)
Note.—WX = water-exchange-modiﬁed, TK = Tofts-Kety, ETK = extended Tofts-Kety, 2CX = two compartment exchange, AATH = adiabatic
approximation to the tissue homogeneity, DP = distributed parameter, BF = total hepatic blood ﬂow (in mL/min/100 g), γ = arterial ﬂow fraction (unitless),
BFA = arterial blood ﬂow (in mL/min/100 g), BFPV = portal blood ﬂow (in mL/min/100 g), BV = blood volume (in mL/100 g), MTT = mean transit time (in
min), PS = capillary wall permeability-surface area product (in mL/min/100 g), vI = fractional interstitial volume (unitless), E = extraction fraction (unitless),
τC = mean intracellular water molecule lifetime (sec), and vC = fractional intracellular volume (unitless). Bold numbers with asterisk (*) indicate a
statistically signiﬁcant difference in the 1000 log-rank permutation test (two-sided P<0.05).
doi:10.1371/journal.pone.0136725.t003
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(10%) in the WX-TK, WX-ETK, WX-AATH, andWX-DP-model-derived vC, respectively, and
falls by 28.4% for an increase of 1 mL/min/100 g in the WX-DP-model-derived BFA.
Overall, the WX-ETK-model-derived vC was not only identified as a statistically significant
prognostic biomarker for 1YS, but was also statistically significantly associated with OS.
Fig 3. Kaplan-Meier curves for kinetic parameters predictive of 1-year survival.Cross-validated Kaplan-Meier plots for (A) arterial flow fraction (γ) and
(B) fractional interstitial volume (vI) derived from the water-exchange-modified Tofts-Kety (WX-TK) model, and (C) mean intracellular water molecule lifetime
(τC) and (D) fractional intracellular volume (vC) derived from the water-exchange-modified extended Tofts-Kety (WX-ETK) model. Survival of patients with
advanced HCC treated with sunitinib was better with γ over 0.833 and vI over 0.300 in theWX-TKmodel, and with τC at most 0.927 sec and vC at most 0.611
in the WX-ETKmodel.
doi:10.1371/journal.pone.0136725.g003
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Discussion
Several studies have assessed the impact of water exchange on the estimation of pharmacoki-
netic parameters, but no definite conclusions have been reached about the significance of water
exchange effects in clinical practice. Bains et al. analyzed DCE-MRI data by using the WX-2CX
model under the FXL and no-exchange-limit conditions, and they compared kinetic parame-
ters derived from DCE-MRI with those obtained from exchange-insensitive DCE-CT in blad-
der cancer [33]. They concluded that the cell-to-interstitium water transfer rate (KCI) has a
negligible effect on estimates of kinetic parameters, whereas the blood-to-interstitium water
transfer rate (KBI) influences estimates of the fractional plasma volume (vP). Huang et al. com-
pared the FXL standard and shutter-speed (fast-exchange regime) approaches of the TK
model, and they demonstrated that relieving of the FXL constraint leads to a higher perfor-
mance for breast cancer diagnosis [11]. Using computer simulations in the WX-ETK model,
Paudyal et al. demonstrated that the effect of a variation of KBI is significant for vP and is mini-
mal for the transfer constant (KTrans = EF/VT) and the fractional interstitial volume (vI) when
KCI is held constant, whereas K
Trans and vI are influenced by a variation in KCI when KBI is held
constant [34]. Using simulated DCE-MRI data, Zhang and Kim assessed four different kinetic
models (FXL standard ETK, shutter-speed ETK, FXL standard AATH, and WX-AATH mod-
els), and they found that KTrans, vI, and vP values estimated from the WX-AATHmodel had
the highest accuracy [35]. Because the rate of water exchange is related to the cell type, size,
shape, and membrane permeability [10], the vascular-interstitial and cellular-interstitial water
exchange can vary significantly between normal and tumor tissue [36]. Therefore, DCE-MRI
yields a variety of water exchange regimes, and here we focused on a water exchange paradigm
based on a full 2SX model [14] or a full 3S2X model [34] that can fully describe the effects from
fast to intermediate or slow water exchange (see S1 Appendix). To the authors’ knowledge, this
is the first comparative study that identified a prognostic WX tracer kinetic model and parame-
ter for 1YS and OS of patients with advanced HCC who received sunitinib monotherapy.
Table 4. Results of univariate Cox’s proportional hazards regression analysis of parameters in terms of overall survival.
Parameter Hazard ratio (P-value)
WX-TK WX-ETK WX-2CX WX-AATH WX-DP
BF 0.785 (0.217) 0.747 (0.138) 0.717 (0.076) 0.680 (0.092) 0.693 (0.092)
γ 0.879 (0.562) 0.961 (0.890) 0.927 (0.747) 0.843 (0.376) 0.792 (0.198)
BFA 0.753 (0.063) 0.796 (0.203) 0.757 (0.093) 0.734 (0.051) 0.716 (0.025)*
BFPV 1.183 (0.248) 0.930 (0.564) 1.012 (0.914) 1.049 (0.760) 1.076 (0.684)
BV 0.805 (0.362) 0.687 (0.218) 0.660 (0.055) 0.557 (0.069) 0.642 (0.110)
MTT 1.247 (0.166) 1.125 (0.695) 1.356 (0.165) 1.371 (0.180) 1.275 (0.266)
PS 0.816 (0.272) 0.815 (0.307) 0.756 (0.173) 0.747 (0.195) 0.959 (0.829)
vI 0.438 (0.053) 0.660 (0.307) 0.942 (0.788) 0.660 (0.332) 0.577 (0.196)
E 1.975 (0.804) 1.656 (0.612) 1.331 (0.541) 1.322 (0.694) 1.181 (0.373)
τC 0.821 (0.424) 1.353 (0.415) 1.237 (0.326) 1.031 (0.883) 1.053 (0.828)
vC 21.51 (0.034)* 8.418 (0.038)* 4.109 (0.094) 10.14 (0.028)* 4.213 (0.041)*
Note.—WX = water-exchange-modiﬁed, TK = Tofts-Kety, ETK = extended Tofts-Kety, 2CX = two compartment exchange, AATH = adiabatic
approximation to the tissue homogeneity, DP = distributed parameter, BF = total hepatic blood ﬂow (in mL/min/100 g), γ = arterial ﬂow fraction (unitless),
BFA = arterial blood ﬂow (in mL/min/100 g), BFPV = portal blood ﬂow (in mL/min/100 g), BV = blood volume (in mL/100 g), MTT = mean transit time (in
min), PS = capillary wall permeability-surface area product (in mL/min/100 g), vI = fractional interstitial volume (unitless), E = extraction fraction (unitless),
τC = mean intracellular water molecule lifetime (sec), and vC = fractional intracellular volume (unitless). Bold numbers with asterisk (*) indicate a
statistically signiﬁcant difference in the 1000 permutation test for hazard ratio in univariate Cox proportional hazards analysis (two-sided P<0.05).
doi:10.1371/journal.pone.0136725.t004
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Our results showed that the WX-ETK-model-derived vC was identified as the most effective
prognostic biomarker for OS and 1YS, which was higher in the high-risk than in the low-risk
group. We assume that these results are associated with tumor hypoxia. Although HCC is a
highly angiogenic cancer, it is also characterized by hypoxia that promotes HCC growth, pro-
gression, angiogenesis, and resistance to therapies [37]. Thus, the high-risk patients may have
relatively more hypoxic HCC [38]. In a hypoxic environment, the mitochondrial oxygen con-
sumption rate and adenosine triphosphate (ATP) production are reduced, which hinders inter
alia active transport into tumor cells [39]. The reduction of ATP by a decreased oxygen supply
causes disturbances in membrane ion translocation that result in cell swelling, which may
induce high vC [40]. On the other hand, Heider et al. [41] demonstrated that the tumor blood
flow was correlated positively with tumor oxygenation in a CT perfusion study of cervical can-
cer. Thus, it is assumed that low tumor BFA is associated with a hypoxic tumor microenviron-
ment, which leads to poor-outcome-promoting oncogenic mutations, cell survival, and more
aggressive behavior of tumors [42]. Besides, low tumor BFA, which leads the disturbed micro-
circulation of antiangiogenic agents and the deterioration of their diffusion conditions, may
result in poor OS of HCC patients treated with sunitinib [12,39,43].
Our results also showed that the parameters that were found to be statistically significant
prognostic biomarkers for 1YS (the WX-TK-model-derived γ and vI) were not necessarily sta-
tistically significantly associated with OS. In contrast, the WX-DP-model-derived BFA, and the
WX-TK, WX-AATH andWX-DP-model-derived vC were not statistically significant prognos-
tic biomarkers for 1YS, although they were statistically significantly associated with OS. The
time scale for events can be classified as either continuous or discrete, and the methods applied
to one type of time scale do not necessarily apply to the other [44]. A fundamental problem
with methods based on dividing the timeline into discrete intervals is the loss of information.
Therefore, our results suggest that analyzing both continuous- and discrete-time events may be
necessary for finding a robust prognostic biomarker.
As antiangiogenic agents might exert different pharmacokinetic effects on tumor flow and
permeability, a method that can separately estimate the plasma flow F (in mL/min) and PS
may be of central importance for understanding tissue hemodynamics. The early version of the
TK model, which has been used most frequently, facilitates the extraction of the volume trans-
fer constant KTrans (in min-1), the physiologic interpretation of which reflects a combination of
F and PS [15], but it has been known that their separate estimates are impossible with the TK
model. The relative magnitude of PS and F determines E, i.e., the fraction of the mass of CA
arriving at the tissue which leaks into the interstitial space in a single passage through the
vasculature.
Under the mixed flow- and permeability-limited condition, KTrans = EF/VT [13,15], where VT
is the examined tissue volume (in mL), and F/VT is the tissue perfusion (in mL/min/mL). With
further assumption that vP vI, a single compartment TKmodel can be derived (see S1 Appen-
dix). The original TKmodel additionally presumed that CA in the plasma compartment can be
neglected (i.e., vPﬃ 0) [45]. However, a separate determination of E and F/VT is impossible with
the assumption that vPﬃ 0. In this study, we refined the TK model parameterization so that
KTrans was decomposed into E and F/VT, by assuming that vP vI. The assumption of vP vI
leads to CT(t)ﬃ vICI(t), where CI(t) is the CA concentration in the interstitial compartment, and
thereby the capillary transit time VP/F (in min) and the capillary leakage time VP/PS (in min) are
negligible, where VP = vPVT is the plasma volume (in mL). However, their reciprocals, F/VP (in
mL/min/mL) and PS/VP (in mL/min/mL), are both infinite if vPﬃ 0. Because F and PS cannot be
calculated without vP (i.e., E becomes undefined), the assumption that vPﬃ 0 may contradict
with the original TK model. On the other hand, if vP 6¼ 0, then F/VP and PS/VP are finite,
and thus F/VT = vPF/VP = vIF/VI and PS/VT = vPPS/VP = vIPS/VI, where VI = vIVT = (vI/vP)VP
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is the interstitial volume (in mL), are not only calculable, but also E can be defined (e.g.,
E ¼ 1 eðPS=VPÞ=ðF=VPÞ). As a result, F and PS can be measured separately with our new parame-
terization rules of the TKmodel. These parameterization rules, which have originally been pro-
posed by Brix et al. for evaluation of the 2CXmodel [16], apply to all of the kinetic models
considered in this study (see S1 Appendix), and the enable fair comparisons among different
kinetic models. Even if parameterization rules are different between the original approaches and
our methods on tracer kinetic modeling, the mass balance principle of CA in the capillary-tissue
system is identical for them.
To date, very few data have been reported on the issue of limited vascular-interstitial water
exchange and its effect on DCE-MRI. Here, we assumed that the vascular-interstitial exchange
behavior would virtually be identical between the CA (Gd-DTPA) and water molecules (see S1
Appendix). In the absence of the CA, water exchange is usually regarded as being in the FXL
[8,14], but in its presence, it enters the interstitium from the plasma and increases the relaxa-
tion rate of interstitial water while the T1 of water in the cell remains the same, which may lead
to significant transient sorties away from the precontrast water exchange state. Even though
water molecules are much lighter (ﬃ18 g/mol) than Gd-DTPA molecules (Magnevist, 938 g/
mol), and the self-diffusion coefficient of water (D = 2.2 × 10−9 m2/sec) is higher than that of
Gd-DTPA (Magnevist, D = 2.6 × 10−10 m2/sec) [46], it should be noted that slow or fast water
exchange does not refer directly to the speed with which the water molecule moves between the
two spaces, but to the ratio of this motion to the difference in relaxation rates of the two spaces
[47]. If the two spaces have identical relaxation rates, they will always be described as being in
the FXL but slowly the water molecules exchange between them, because no distinction can be
made between their relaxation properties. Contrarily, if the two spaces have an order-of-mag-
nitude difference in their each relaxation rates, they will be in the slow exchange regime even
though water moves very rapidly between them, because their relaxation properties will always
be the major focus of the decision of water exchange [48].
The addition of CA to the interstitial space does not change the motion of water molecules,
but it increases the intrinsic relaxation rate of the interstitial space. Given the large difference
in relaxation rates in the two spaces immediately after the CA injection, the water exchange
would significantly depart from the FXL, because the CA might not have had time to pass into
the interstitial space while being present in high concentration in the intravascular space. For
example, with an intact blood-brain barrier that has very low permeability, the vascular-inter-
stitial water exchange slowly approaches the limit during the first pass of a bolus of Gd-DTPA
[49]. On the other hand, if the CA enters the interstitial space quickly, the effect of slow water
exchange is short-lived. For example, in the heart, where the first-pass extraction of Gd-DTPA
is significant, the slow-water-exchange effect decreases quickly [49]. As such, the vascular-
interstitial water exchange with typical CA concentrations is in the slow- to intermediate-
exchange regime [8], and the trends in water mobility to the difference in relaxation rates of
the two spaces seem to be more like Gd-DTPA exchange behavior rather than the inherent
speed of movement of the water. Furthermore, even if the vascular-interstitial water exchange
rates may appear to be faster in tumors where the vascular permeability is larger, they are prob-
ably dependent on the geometric and hemodynamic heterogeneity of microvascular networks
as well as the microvascular permeability.
HCC is a heterogeneous disease with multiple etiologies that has an abnormal blood flow and
is excessively leaky [38]. Setting the water exchange rate to a value reported in the literature is
unlikely to reflect a complex phenomenon involving multiple exchange behaviors in the context
of a spatially heterogeneous tumor microenvironment. As an alternative, model fitting can be
done by considering the mean intravascular water molecule lifetime τB as an additional free
Water-Exchange DCE-MRI as a Prognostic Imaging Biomarker for HCC
PLOSONE | DOI:10.1371/journal.pone.0136725 September 14, 2015 13 / 18
parameter independent from the exchange rate of CA [9]. However, the accuracy and precision in
such an approach may be low [35]. The reason for this is not obvious, but one could hypothesize
that the estimation of τB might be difficult without the aid of tracer kinetic parameters because τB
is calculated based on the ratio of BV to PS [8]. In contrast, τC can be used as an independent vari-
able [14], because Gd-DTPA does not permeate the cell membrane and pass into the intracellular
space, whereas the cellular-interstitial water exchange is intermediate to fast [8]. Therefore,
although the speed of intercompartmental water exchange cannot be set to a single value, our
approach would be a plausible implicit compromise for the evaluation of tumor angiogenesis.
When more complex models such as WX kinetic models are used for data analysis, the
goodness of fit alone may not be sufficient to ensure that the estimated parameters truly reflect
the corresponding biophysical properties of the tissue [35]. Therefore, in this study, we com-
pared the prognostic ability for patient survival among different WX kinetic models under the
same experimental conditions to identify clinically relevant biomarkers. Although such bio-
markers may provide clinical realism and biologic validity, the precision in the parameter esti-
mates may be influenced by the low temporal resolution of the DCE-MRI data. In addition,
because the data-fitting process is formulated as an optimization task, the nonlinear character-
istics of the kinetic model may lead to a convergence problem. Moreover, as DCE-MRI data
are obtained sequentially at fixed time points, issues of discontinuity may arise which are
caused by the initial step of the impulse residue function at the bolus arrival time (any model)
and at the capillary transit time (AATH and DP models) [25]. To mitigate these problems, we
first imposed upper and lower boundary constraints to the parameter values in order to avoid
its over- and under-fitting. Second, we employed standard gradient-based optimization algo-
rithms with an explicit analytic solution via continuous-time-domain convolution between the
hepatic dual-input function (AIF and PVIF) and QT(t) for each kinetic model, in which the
WX dual-input kinetic models were extended include the primary (first-pass) and recirculation
bolus arrival times as a free continuous parameter tLag,T (see S1 Appendix).
It should also be noted that both the AIF and PVIF hold the same smooth and integrable
functional forms, so that their scaling constants and bolus arrival times constrain kinetic
parameter values at any temporal resolution. Therefore, the occurrences of discontinuities in
the impulse residue function do not necessarily result in a discontinuous or nondifferentiable
CT(t), which poses difficulties for curve-fitting algorithms employing gradient-based optimiza-
tion schemes. Although some parameters such as BF, BV, and tLag,T might be influenced by the
low temporal resolution of the DCE-MRI data, the continuous-time analytic formulations of
CT(t) would lower the potential bias in parameter estimates [25]. A more precise analysis may
require a higher temporal resolution. Investigation of the impact of modifications in DCE-MRI
acquisition techniques on kinetic parameters was beyond the scope of this study, although it is
an important issue that deserves more thorough investigation in future studies.
Accurate estimates of vP is clinically useful for assessing the integrity of the tumor microvas-
culature [50,51] and for monitoring the response to antiangiogenic therapy [52,53]. Although
BV, in which the ratio BV/vP is a constant, was not chosen as a prognostic biomarker in this
study, vP might have an influence on estimation of vC. The FXL assumption may bias the accu-
racy and reproducibility of vP measurements because of the restricted vascular-interstitial
water exchange [54]. In addition, if the concentration of CA in the interstitial space were to
reach a significant level, the cellular-interstitial water exchange would depart from the FXL
[10,14,55]. Because the mixing phase, during which the injected bolus is mixed with the blood
plasma and interstitial compartments, lasts up to about 2 minutes [45], the effects of slow cellu-
lar-interstitial water exchange would be felt during the longer total measurement time (4.5
minutes) in this study. The full 3S2X model determines kinetic parameters, including both the
vascular-interstitial and cellular-interstitial water transfer rates, but the full 2SX model includes
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only the cellular-interstitial water transfer rate [9]. Therefore, the fact that the full 3S2X model
(WX-ETK model) outperformed the full 2SX model (WX-TK model) in this study confirms
that the inclusion of the vascular-interstitial water exchange is necessary for the effective risk
assessment of tumor characteristics such as vascularity, cellularity, and hypoxia.
There are limitations to our study. First, this is a retrospective analysis on a relatively small
number of patients from a Phase II clinical trial, although it serves as a pilot comparative study.
Second, the single-arm study design of the clinical trial did not allow us to evaluate the predictive
value of the kinetic parameters as imaging biomarkers; instead, the prognostic value of the kinetic
parameters was evaluated by means of statistical resampling methods. Third, the prognostic
value was evaluated on the kinetic parameters only on the pretreatment DCE-MRI, because the
primarily clinical goal of this study was to find a prognostic imaging biomarker that estimates the
prognosis of patients before the treatment starts. Evaluation of the prognostic value of the kinetic
parameters of the post-treatment DCE-MRI, which may have an effect on the 1YS and OS,
remains for further study. Forth, survival risk estimation based on the selected cut-off values of
the kinetic parameters with use of ROC analysis may result in an overestimate of the prognostic
value of the parameters. Ideally, this type of analysis should have been performed based on large
independent training and testing data sets. When the data size is not large enough, cross-valida-
tion methods are known to be more efficient than splitting of the data set into training and test-
ing subsets [29]. We thus performed LOOCV and permutation tests to obtain an estimate of the
prognostic value of the kinetic parameters. We believe that we were able to estimate a reasonably
unbiased and generalizable prognostic value of the kinetic parameters with respect to 1YS as well
as association with OS. Finally, the clinical value of the prognostic imaging biomarker found in
this study may be limited to the patients who are treated with sunitinib monotherapy. Currently,
sunitinib monotherapy is not an accepted treatment for patients with advanced HCC in clinical
practice. Thus, the clinical value of the prognostic imaging biomarker for the patients treated
with sorafenib, the current standard treatment, and other antiangiogenic therapies remains
unknown.We believe, however, that the findings on the prognostic value of the kinetic parame-
ters from DCE-MRI data have significant implications for antiangiogenic agents, and thus war-
rant further validation in larger prospective studies.
Conclusion
In conclusion, kinetic parameters derived fromWX dual-input tracer kinetic models of
DCE-MRI data can be effective prognostic biomarkers for survival of patients with advanced
HCC. The choice of kinetic models influences the predictability of survival, and the WX-ETK-
model-derived vC was found to be an effective prognostic biomarker for both 1YS and OS in
patients with advanced HCC who received sunitinib monotherapy. The fact that the vC bio-
marker is available only from the WX kinetic formulation indicates that the water transport
properties of cells is an important predictor of cancer cell development.
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